PO-77 | Real-world evidence of Atogepant efficacy in patients unresponsive to anti-CGRP monoclonals
Matteo Cortinovis, Marco Bolchini, Paola Zavarise, Giulia Campana, Giorgio Dalla Volta | Headache Center, Istituto Clinico Città di Brescia, Gruppo San Donato, Brescia, Italy
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Background: Migraine is a prevalent and disabling neurological disorder, especially in its chronic and high-frequency episodic forms. Monoclonal antibodies (mAbs) targeting the CGRP pathway have improved outcomes for many patients, yet a subset remains refractory. Atogepant, an oral CGRP receptor antagonist, represents a novel therapeutic option. This study assesses the real-world efficacy of Aquipta in patients with chronic or high-frequency episodic migraine who previously failed anti-CGRP mAb therapy.
Methods: We conducted an observational study involving 36 patients, representing approximately 15% of our total population treated with anti-CGRP monoclonal antibodies. Among them, 34 had been treated with Galcanezumab and 2 with Fremanezumab. A total of 18 patients (16 with Galcanezumab and 2 with Fremanezumab) had chronic migraine, while the remaining 18 had high-frequency episodic migraine. All patients received Atogepant 60 mg once daily. Treatment response was evaluated based on self-reported reduction in monthly migraine frequency. Statistical analysis was conducted using the chi-square (χ²) test.
Results: Thirty-two patients (89%) reported clinical benefit with Atogepant: 30 of those previously treated with Galcanezumab and both treated with Fremanezumab. Four patients (11%) discontinued Aquipta: three due to lack of efficacy and one due to both lack of efficacy and adverse events (confusion, nausea, vertigo). The chi-square test demonstrated a significant association between Aquipta treatment and migraine frequency reduction (χ² = 22.78, p < 0.0001).
Conclusion: In this real-world cohort of patients unresponsive to anti-CGRP monoclonal antibodies, Atogepant showed substantial efficacy, with nearly 90% reporting clinical benefit. These findings support Atogepant as a valuable therapeutic alternative in patients with chronic and high-frequency episodic migraine who have not responded to prior mAb treatments.
Downloads
Citations
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.